Literature DB >> 26863915

Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern.

Florian Haller1, Jasmin Knopf1, Anne Ackermann1, Matthias Bieg2, Kortine Kleinheinz2, Matthias Schlesner2, Evgeny A Moskalev1, Rainer Will3, Ali Abdel Satir4, Ibtihalat E Abdelmagid5, Johannes Giedl1, Roman Carbon6, Oliver Rompel7, Arndt Hartmann1, Stefan Wiemann3,8, Markus Metzler9, Abbas Agaimy1.   

Abstract

Neoplasms with a myopericytomatous pattern represent a morphological spectrum of lesions encompassing myopericytoma of the skin and soft tissue, angioleiomyoma, myofibromatosis/infantile haemangiopericytoma and putative neoplasms reported as malignant myopericytoma. Lack of reproducible phenotypic and genetic features of malignant myopericytic neoplasms have prevented the establishment of myopericytic sarcoma as an acceptable diagnostic category. Following detection of a LMNA-NTRK1 gene fusion in an index case of paediatric haemangiopericytoma-like sarcoma by combined whole-genome and RNA sequencing, we identified three additional sarcomas harbouring NTRK1 gene fusions, termed 'spindle cell sarcoma, NOS with myo/haemangiopericytic growth pattern'. The patients were two children aged 11 months and 2 years and two adults aged 51 and 80 years. While the tumours of the adults were strikingly myopericytoma-like, but with clear-cut atypical features, the paediatric cases were more akin to infantile myofibromatosis/haemangiopericytoma. All cases contained numerous thick-walled dysplastic-like vessels with segmental or diffuse nodular myxohyaline myo-intimal proliferations of smooth muscle actin-positive cells, occasionally associated with thrombosis. Immunohistochemistry showed variable expression of smooth muscle actin and CD34, but other mesenchymal markers, including STAT6, were negative. This study showed a novel variant of myo/haemangiopericytic sarcoma with recurrent NTRK1 gene fusions. Given the recent introduction of a novel therapeutic approach targeting NTRK fusion-positive neoplasms, recognition of this rare but likely under-reported sarcoma variant is strongly encouraged.
Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  NTRK1; haemangiopericytoma; infantile fibrosarcoma; myopericytic sarcoma; sarcoma

Mesh:

Substances:

Year:  2016        PMID: 26863915     DOI: 10.1002/path.4701

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  25 in total

1.  Recurrent SRF-RELA Fusions Define a Novel Subset of Cellular Myofibroma/Myopericytoma: A Potential Diagnostic Pitfall With Sarcomas With Myogenic Differentiation.

Authors:  Cristina R Antonescu; Yun-Shao Sung; Lei Zhang; Narasimhan P Agaram; Christopher D Fletcher
Journal:  Am J Surg Pathol       Date:  2017-05       Impact factor: 6.394

2.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Authors:  Alexander Drilon; Salvatore Siena; Sai-Hong Ignatius Ou; Manish Patel; Myung Ju Ahn; Jeeyun Lee; Todd M Bauer; Anna F Farago; Jennifer J Wheler; Stephen V Liu; Robert Doebele; Laura Giannetta; Giulio Cerea; Giovanna Marrapese; Michele Schirru; Alessio Amatu; Katia Bencardino; Laura Palmeri; Andrea Sartore-Bianchi; Angelo Vanzulli; Sara Cresta; Silvia Damian; Matteo Duca; Elena Ardini; Gang Li; Jason Christiansen; Karey Kowalski; Ann D Johnson; Rupal Patel; David Luo; Edna Chow-Maneval; Zachary Hornby; Pratik S Multani; Alice T Shaw; Filippo G De Braud
Journal:  Cancer Discov       Date:  2017-02-09       Impact factor: 39.397

Review 3.  Molecular profiling of sarcomas: new vistas for precision medicine.

Authors:  Tariq Al-Zaid; Wei-Lien Wang; Neeta Somaiah; Alexander J Lazar
Journal:  Virchows Arch       Date:  2017-06-29       Impact factor: 4.064

4.  A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report.

Authors:  Ning Zhou; Reinhold Schäfer; Tao Li; Meiyu Fang; Luying Liu
Journal:  BMC Cancer       Date:  2018-08-22       Impact factor: 4.430

5.  [Minutes of the AG Knochen-, Gelenk- und Weichgewebspathologie : DGB-Conference on 19 May 2016].

Authors:  S Scheil-Bertram; V Krenn
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

6.  Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma.

Authors:  Yu-Chien Kao; Christopher D M Fletcher; Rita Alaggio; Leonard Wexler; Lei Zhang; Yun-Shao Sung; Dicle Orhan; Wei-Chin Chang; David Swanson; Brendan C Dickson; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-01       Impact factor: 6.394

Review 7.  New fusion sarcomas: histopathology and clinical significance of selected entities.

Authors:  Markku Miettinen; Anna Felisiak-Golabek; Alejandro Luiña Contreras; John Glod; Rosandra N Kaplan; Jonathan Keith Killian; Jerzy Lasota
Journal:  Hum Pathol       Date:  2019-01-08       Impact factor: 3.466

8.  Morphologic Overlap Between Inflammatory Myofibroblastic Tumor and IgG4-related Disease: Lessons From Next-generation Sequencing.

Authors:  Martin S Taylor; Abhijit Chougule; Allsion R MacLeay; Pawel Kurzawa; Ivan Chebib; Long Le; Vikram Deshpande
Journal:  Am J Surg Pathol       Date:  2019-03       Impact factor: 6.394

9.  Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors.

Authors:  Narasimhan P Agaram; Lei Zhang; Yun-Shao Sung; Chun-Liang Chen; Catherine T Chung; Cristina R Antonescu; Christopher Dm Fletcher
Journal:  Am J Surg Pathol       Date:  2016-10       Impact factor: 6.394

Review 10.  What's new in fibroblastic tumors?

Authors:  Susan M Armstrong; Elizabeth G Demicco
Journal:  Virchows Arch       Date:  2019-12-11       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.